Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series
Tocilizumab maybe a useful therapeutic option in refractory GO coexisting with OMG. However, considering the limitation of a retrospective study, short follow up period and small sample size of this study, randomized controlled studies are needed to validate our results.
Authors
- Qilin Cheng (ORCID: https://orcid.org/0000-0001-9123-4838)
- Ning Ma (ORCID: https://orcid.org/0000-0001-7315-8835)
- Ping Wang (ORCID: https://orcid.org/0000-0002-3851-2779)
- Qiong Zhang (ORCID: https://orcid.org/0000-0001-5001-8434)
- Yangjun Li (ORCID: https://orcid.org/0000-0001-7206-452X)
- Chenjun Guo
- Shaobo Zhang (ORCID: https://orcid.org/0000-0003-0005-8651)
Institutions
- People 's Liberation Army 451 Hospital (CN)
- Xi'an Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- BMC Ophthalmology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s12886-024-03779-x
- Citations
- 1
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- National Natural Science Foundation of China
- Yakult Bio-Science Foundation
- Key Research and Development Projects of Shaanxi Province